Explore

Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects

GSK Reports Positive Results for Ovarian Cancer Treatment, Boosting Future Sales Prospects
Trendline Trendline
Innate Pharma Announces Annual General Meeting for Shareholders

Innate Pharma Announces Annual General Meeting for Shareholders

Innate Pharma Announces Annual General Meeting for Shareholders
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Trendline Trendline
IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape

IDEAYA and Servier's PKC Drug Shows Promise in Uveal Melanoma Trial, Potentially Changing Treatment Landscape
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development
Reuters Reuters
GSK sees blockbuster potential in targeted cancer therapy after promising early data

GSK sees blockbuster potential in targeted cancer therapy after promising early data

By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced, hard-to-treat cancers.